Literature DB >> 11337345

Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy.

M M Thurnher1, M J Post, A Rieger, C Kleibl-Popov, C Loewe, E Schindler.   

Abstract

BACKGROUND AND
PURPOSE: Recent studies have shown the beneficial effect of highly active antiretroviral therapy (HAART) in AIDS-related progressive multifocal leukoencephalopathy (PML). The purpose of our study was to evaluate the initial and follow-up imaging findings and survival in patients with PML who were treated with HAART.
METHODS: The clinical course and MR imaging findings on initial and follow-up MR studies in four consecutive AIDS patients with PML who were treated with HAART are described.
RESULTS: Two patients were short-term survivors and died after 3 months. Two patients are still alive, with a survival time of 22 and 43 months, respectively. On initial MR studies, more extensive white matter changes were seen in the short-term survivors. Development of a mass effect and temporary enhancement (in one patient) was observed in two HAART responders on follow-up MR studies. Increased hypointensity on T1-weighted images with concomitant low signal on fluid-attenuated inversion-recovery fast spin-echo (FLAIR-FSE) images was seen in two responders, representing leukomalacia. Atrophic changes of the involved areas of the brain, consistent with burnt out PML lesions, were seen in two long-term survivors. In the short-term survivors, increased hypointensity was present on T1-weighted images with increased high signal on FLAIR-FSE images, representing progressive destructive disease.
CONCLUSION: Our results suggest that a clinical and radiologic response can be seen in some patients with AIDS-associated PML on HAART while in others there may be no beneficial response. Development of a mass effect and temporary enhancement on MR images in the early phase of treatment might represent positive predictive factors for prolonged survival.

Entities:  

Mesh:

Year:  2001        PMID: 11337345      PMCID: PMC8174932     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  26 in total

1.  Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients.

Authors:  J Collazos; J Mayo; E Martínez; M S Blanco
Journal:  AIDS       Date:  1999-07-30       Impact factor: 4.177

Review 2.  Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare.

Authors:  J R Berger; M Concha
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

3.  Contrast-enhancing progressive multifocal leukoencephalopathy: radiological and pathological correlations: case report.

Authors:  H H Woo; A R Rezai; E A Knopp; H L Weiner; D C Miller; P J Kelly
Journal:  Neurosurgery       Date:  1996-11       Impact factor: 4.654

4.  Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy.

Authors:  W Tantisiriwat; P Tebas; D B Clifford; W G Powderly; C J Fichtenbaum
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

5.  Progressive multifocal leukoencephalopathy following initiation of highly active antiretroviral therapy.

Authors:  J Mayo; J Collazos; E Martínez
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

Review 6.  Antiretroviral drugs and the central nervous system.

Authors:  R H Enting; R M Hoetelmans; J M Lange; D M Burger; J H Beijnen; P Portegies
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

7.  Regression of progressive multifocal encephalopathy with highly active antiretroviral therapy.

Authors:  M Baqi; W Kucharczyk; S L Walmsley
Journal:  AIDS       Date:  1997-10       Impact factor: 4.177

8.  Progressive multifocal leukoencephalopathy: contrast enhancement on CT scans and MR images.

Authors:  A L Wheeler; C L Truwit; B K Kleinschmidt-DeMasters; W R Byrne; R N Hannon
Journal:  AJR Am J Roentgenol       Date:  1993-11       Impact factor: 3.959

9.  Clinical and virological monitoring during treatment with intrathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  A De Luca; M L Giancola; A Cingolani; A Ammassari; L Gillini; R Murri; A Antinori
Journal:  Clin Infect Dis       Date:  1999-03       Impact factor: 9.079

10.  Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy.

Authors:  J R Berger; R M Levy; D Flomenhoft; M Dobbs
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

View more
  30 in total

1.  Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial?

Authors:  Renaud A Du Pasquier; Igor J Koralnik
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 2.  The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature.

Authors:  Paola Cinque; Simona Bossolasco; Anna Maria Brambilla; Antonio Boschini; Cristina Mussini; Chiara Pierotti; Adriana Campi; Salvatore Casari; Davide Bertelli; Maurizio Mena; Adriano Lazzarin
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 3.  The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections.

Authors:  David F Tate; Rola Khedraki; Daniel McCaffrey; Daniel Branson; Jeffrey Dewey
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 4.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

5.  Use of diffusion-weighted imaging to evaluate the initial response of progressive multifocal leukoencephalopathy to highly active antiretroviral therapy: early experience.

Authors:  C Buckle; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2010-04-01       Impact factor: 3.825

6.  Immune reconstitution inflammatory syndrome and cerebral toxoplasmosis.

Authors:  R F Cabral; P R Valle Bahia; E L Gasparetto; L Chimelli
Journal:  AJNR Am J Neuroradiol       Date:  2010-05-27       Impact factor: 3.825

Review 7.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

8.  Characterization of white matter degeneration in elderly subjects by magnetic resonance diffusion and FLAIR imaging correlation.

Authors:  Wang Zhan; Yu Zhang; Susanne G Mueller; Peter Lorenzen; Stathis Hadjidemetriou; Norbert Schuff; Michael W Weiner
Journal:  Neuroimage       Date:  2009-02-20       Impact factor: 6.556

9.  Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations.

Authors:  M Bergui; G B Bradac; K K Oguz; A Boghi; C Geda; G Gatti; D Schiffer
Journal:  Neuroradiology       Date:  2003-10-31       Impact factor: 2.804

Review 10.  Progressive multifocal leukoencephalopathy in HIV-1 infection.

Authors:  Paola Cinque; Igor J Koralnik; Simonetta Gerevini; Jose M Miro; Richard W Price
Journal:  Lancet Infect Dis       Date:  2009-10       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.